A Versatile Adeno-Associated Virus Vector Producer Cell Line Method for Scalable Vector Production of Different Serotypes
- 1 May 2011
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 22 (5) , 613-624
- https://doi.org/10.1089/hum.2010.241
Abstract
Application of adeno-associated virus (AAV) vector in large animal studies and clinical trials often requires high-titer and high-potency vectors. A number of currently used vector production methods, based on either transient transfection or helper virus infection of cell lines, have their advantages and limitations. We previously developed a 293-cell–based producer cell line method for high-titer and high-potency AAV2 vectors. Similar to several other methods, however, it requires multiple cloning steps for the vector and packaging plasmids and a two-step transfection and selection for stable cell lines. Here we report a simplified method with several key improvements and advantages: (1) a one-step cloning of AAV vector cassette into the serotype-specific packaging plasmid; (2) a single plasmid transfection and selection for stable AAV vector producer cell lines; (3) high vector yields of different serotypes, e.g., AAV2, 8, and 9, upon infection with an E1A/E1B-deleted helper adenovirus; (4) efficient packaging of both single-stranded and double-stranded (self-complementary) AAV vectors; and (5) efficient packaging of large AAV cassettes such as a mini-dystrophin vector (5.0 kb). All cell lines were stable with growth rates identical to the parental 293 cells. The vector yields were consistent among serotypes, with 5 × 1013 to 8 × 1013 vector genome particles per Nunc cell factory (equivalent to 40 15-cm plates). The vectors showed high potency for in vitro and in vivo transduction. In conclusion, the simple and versatile AAV producer cell line method can be useful for large scale AAV vector production in preclinical and clinical studies. Yuan and colleagues describe a streamlined 293 cell-based producer cell line method for producing high-titer and high-potency AAV vectors. Using this method, the authors were able to produce AAV8 and AAV9 in addition to AAV2. This scalable method was found to be efficient in producing both singlestranded AAV and self-complementary AAV vectors.Keywords
This publication has 50 references indexed in Scilit:
- Sustained alpha‐sarcoglycan gene expression after gene transfer in limb‐girdle muscular dystrophy, type 2DAnnals of Neurology, 2010
- Dystrophin Immunity in Duchenne's Muscular DystrophyNew England Journal of Medicine, 2010
- Rapid, Simple, and Versatile Manufacturing of Recombinant Adeno-Associated Viral Vectors at ScaleHuman Gene Therapy, 2010
- Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscleNature Biotechnology, 2010
- Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapyProceedings of the National Academy of Sciences, 2009
- A Versatile Viral System for Expression and Depletion of Proteins in Mammalian CellsPLOS ONE, 2009
- Large-Scale Adeno-Associated Viral Vector Production Using a Herpesvirus-Based System Enables Manufacturing for Clinical StudiesHuman Gene Therapy, 2009
- A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selectionProceedings of the National Academy of Sciences, 2009
- Safety and Efficacy of Gene Transfer for Leber's Congenital AmaurosisNew England Journal of Medicine, 2008
- The Cellular TATA Binding Protein Is Required for Rep-Dependent Replication of a Minimal Adeno-Associated Virus Type 2 p5 ElementJournal of Virology, 2005